Aubagio, whose generic name is teriflunomide, is a medication prescribed to treat relapsing forms of multiple sclerosis (MS). It works by modulating the immune system to reduce inflammation and slow the progression of MS symptoms. The question of whether Aubagio can be used long term is important for many patients managing this chronic condition.
Aubagio **can be used long term** under medical supervision. It is designed as a disease-modifying therapy that helps decrease relapse rates and may slow disability progression in people with relapsing MS. While it does not cure MS, its ongoing use aims to maintain disease control over extended periods. Clinical experience and studies have shown that many patients remain on Aubagio for years with continued benefit.
When considering long-term use, several factors come into play:
– **Effectiveness Over Time:** Aubagio has demonstrated sustained efficacy in reducing relapses and slowing brain atrophy associated with MS over months to years of treatment. This suggests it remains beneficial beyond short-term use.
– **Safety Profile:** Long-term safety data indicate that while some side effects may occur—such as liver enzyme elevations or infections—these are generally manageable with regular monitoring by healthcare providers. Patients typically undergo periodic blood tests to check liver function and blood counts during treatment.
– **Monitoring Requirements:** Because teriflunomide affects the immune system, doctors monitor for potential adverse effects like increased risk of infections or liver problems throughout therapy duration. If serious side effects arise, discontinuation or switching therapies might be necessary.
– **Patient Factors:** Individual response varies; some tolerate Aubagio well for many years without major issues, while others may need alternative treatments due to side effects or insufficient disease control.
It’s important not to stop taking Aubagio abruptly without consulting a doctor because sudden discontinuation can lead to worsening symptoms or rebound disease activity. Also, if stopping treatment becomes necessary—for example due to pregnancy planning—there are specific procedures (like accelerated elimination protocols) since teriflunomide stays in the body for an extended time otherwise.
In summary, Aubagio is intended as a long-term therapy option for people living with relapsing forms of multiple sclerosis when prescribed by a neurologist experienced in MS care. Its continued use depends on balancing benefits against risks through regular clinical evaluation and lab testing tailored individually over time. Many patients successfully manage their condition on this medication for years under close medical guidance while maintaining quality of life and reducing relapse frequency compared with no treatment at all.
If you are considering starting or continuing Aubagio long term, discussing your personal health situation thoroughly with your healthcare provider will help ensure safe management aligned with current best practices in MS care.
